Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
PD-134308
|
| gptkbp:CASNumber |
139505-81-6
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:effect |
analgesic
benzodiazepine antidepressant |
| gptkbp:function |
cholecystokinin antagonist
|
| gptkbp:hasMolecularFormula |
C32H32N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
CI-988
|
| gptkbp:IUPACName |
4-[(2,3-dihydro-1H-inden-2-yl)amino]-2-[(4-methylpiperazin-1-yl)methyl]quinazoline-6-carboxamide
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:PubChem_CID |
CHEMBL2105932
60713 |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:studiedBy |
gptkb:depression
pain anxiety |
| gptkbp:target |
gptkb:cholecystokinin_B_receptor
|
| gptkbp:UNII |
6Q1K7F1K1D
|
| gptkbp:bfsParent |
gptkb:CCK-B_receptor
|
| gptkbp:bfsLayer |
7
|